4//SEC Filing
Foy Matthew 4
Accession 0000899243-21-007444
CIK 0001656536other
Filed
Feb 18, 7:00 PM ET
Accepted
Feb 19, 6:59 PM ET
Size
18.2 KB
Accession
0000899243-21-007444
Insider Transaction Report
Form 4
Foy Matthew
Director10% Owner
Transactions
- Conversion
Common Stock
2021-02-17+458,487→ 458,487 total(indirect: See footnote) - Conversion
Common Stock
2021-02-17+247,324→ 705,811 total(indirect: See footnote) - Conversion
Common Stock
2021-02-17+327,852→ 1,033,663 total(indirect: See footnote) - Purchase
Common Stock
2021-02-17$18.00/sh+150,000$2,700,000→ 1,183,663 total(indirect: See footnote) - Conversion
Series A Preferred Stock
2021-02-17−7,119,852→ 0 total(indirect: See footnote)→ Common Stock (458,487 underlying) - Conversion
Series C Preferred Stock
2021-02-17−3,125,000→ 0 total(indirect: See footnote)→ Common Stock (247,324 underlying) - Conversion
Series D Preferred Stock
2021-02-17−1,737,619→ 0 total(indirect: See footnote)→ Common Stock (327,852 underlying)
Footnotes (4)
- [F1]On February 17, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 15.529-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
- [F2]On February 17, 2021, the Series C Preferred Stock automatically converted into Common Stock on a 12.6352-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
- [F3]On February 17, 2021, the Series D Preferred Stock automatically converted into Common Stock on a 5.3-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
- [F4]Held of record by GSK Equity Investments, Limited ("GSK"), an indirect, wholly owned subsidiary of GlaxoSmithKline plc. SR One Capital Management, LP ("S.R. One") is the investment advisor for GSK. Mr. Foy is a partner at S.R. One. Mr. Foy disclaims beneficial ownership of all the shares reported herein and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his proportionate pecuniary interest therein.
Documents
Issuer
Decibel Therapeutics, Inc.
CIK 0001656536
Entity typeother
Related Parties
1- filerCIK 0001842129
Filing Metadata
- Form type
- 4
- Filed
- Feb 18, 7:00 PM ET
- Accepted
- Feb 19, 6:59 PM ET
- Size
- 18.2 KB